



DEFENSE
HEALTH AGENCY

MB&RO

**OFFICE OF THE ASSISTANT SECRETARY OF DEFENSE
HEALTH AFFAIRS**
16401 EAST CENTRETECH PARKWAY
AURORA, CO 80011-9066

**CHANGE 108
6010.57-M
MARCH 24, 2014**

**PUBLICATIONS SYSTEM CHANGE TRANSMITTAL
FOR
TRICARE POLICY MANUAL (TPM), FEBRUARY 2008**

The TRICARE Management Activity has authorized the following addition(s)/revision(s).

CHANGE TITLE: EVOLVING PRACTICE 14-001

CONREQ: 16863

PAGE CHANGE(S): See page 2.

SUMMARY OF CHANGE(S): See page 3.

EFFECTIVE DATE: See page 3.

IMPLEMENTATION DATE: April 7, 2014.

FAZZINI.ANN.NO
REEN.119980227
1

Digitally signed by
FAZZINI.ANN.NOREEN.1199802271
DN: c=US, o=U.S. Government, ou=DoD,
ou=P KI, ou=TMA,
cn=FAZZINI.ANN.NOREEN.1199802271
Date: 2014.03.19 09:35:34 -06'00'

**Ann N. Fazzini
Team Chief, Medical Benefits &
Reimbursement Office (MB&RO)
Defense Health Agency (DHA)**

**ATTACHMENT(S): 22 PAGE(S)
DISTRIBUTION: 6010.57-M**

WHEN PRESCRIBED ACTION HAS BEEN TAKEN, FILE THIS TRANSMITTAL WITH BASIC DOCUMENT.

CHANGE 108
6010.57-M
MARCH 24, 2014

REMOVE PAGE(S)

CHAPTER 1

Section 3.1, pages 1 - 3

CHAPTER 4

Section 6.1, pages 1 - 3

Section 24.5, pages 1 - 4

CHAPTER 5

Section 3.1, pages 3 and 4

APPENDIX A

pages 7 - 14, 29, 30

INSERT PAGE(S)

Section 3.1, pages 1 - 3

Section 6.1, pages 1 - 3

Section 24.5, pages 1 - 4

Section 3.1, pages 3 and 4

pages 17 - 14, 29, 30

SUMMARY OF CHANGES

CHAPTER 1

1. Section 3.1. This change confirms that gastric cancer meets the TRICARE definition of a rare disease, and in accordance with the rare disease policy, Radiofrequency Ablation (RFA) for the treatment of liver metastases from gastric cancer is considered safe and effective. EFFECTIVE DATE: 06/01/10.

CHAPTER 4

2. Section 6.1. This change confirms that sufficient reliable evidence exists to support the determination that single-level, cervical Total Disc Replacement (TDR) using an FDA-approved cervical artificial intervertebral disc for the treatment of cervical Degenerative Disc Disease (DDD), intractable radiculopathy, and/or myelopathy is proven safe and effective. EFFECTIVE DATE: 12/24/12.
3. Section 24.5. This change confirms that Citrullinemia Type 1 (CTLN1) is a rare disease and in accordance with the rare disease policy there is sufficient evidence to support that liver transplantation is safe and effective for the treatment of CTLN1. EFFECTIVE DATE: 05/29/12.

CHAPTER 5

4. Section 3.1. This change confirms that electromagnetic targeting systems used in the delivery of radiotherapy for the treatment of cancer is unproven and excluded from TRICARE coverage. EFFECTIVE DATE: N/A.

APPENDIX A

5. Added new acronyms.

